<collection><source>PubTator</source><date /><key>BioC.key</key><document><id>3189939</id><passage><infon key="name_3">surname:Reddy;given-names:Venkateshwar</infon><infon key="name_2">surname:Wu;given-names:Chunlei</infon><infon key="name_1">surname:Galkin;given-names:Anna V.</infon><infon key="article-id_pmid">22016777</infon><infon key="name_0">surname:Hu;given-names:Yue</infon><infon key="issue">10</infon><infon key="year">2011</infon><infon key="article-id_pmc">3189939</infon><infon key="article-id_publisher-id">PONE-D-11-05185</infon><infon key="alt-title">CAFET Reveals Wnt Signature in Lung Cancer</infon><infon key="article-id_doi">10.1371/journal.pone.0025807</infon><infon key="type">front</infon><infon key="elocation-id">e25807</infon><infon key="volume">6</infon><infon key="license">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</infon><infon key="section_type">TITLE</infon><infon key="journal">PLoS ONE; 2011; 6(10) 25807. doi:10.1371/journal.pone.0025807</infon><infon key="name_5">surname:Minna;given-names:John D.</infon><infon key="name_4">surname:Su;given-names:Andrew I.</infon><infon key="authors">Hu Y, Galkin AV, Wu C, Reddy V, Su AI</infon><offset>0</offset><text>CAFET Algorithm Reveals Wnt/PCP Signature in Lung Squamous Cell Carcinoma</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>74</offset><text>We analyzed the gene expression patterns of 138 Non-Small Cell Lung Cancer (NSCLC) samples and developed a new algorithm called Coverage Analysis with Fisher's Exact Test (CAFET) to identify molecular pathways that are differentially activated in squamous cell carcinoma (SCC) and adenocarcinoma (AC) subtypes. Analysis of the lung cancer samples demonstrated hierarchical clustering according to the histological subtype and revealed a strong enrichment for the Wnt signaling pathway components in the cluster consisting predominantly of SCC samples. The specific gene expression pattern observed correlated with enhanced activation of the Wnt Planar Cell Polarity (PCP) pathway and inhibition of the canonical Wnt signaling branch. Further real time RT-PCR follow-up with additional primary tumor samples and lung cancer cell lines confirmed enrichment of Wnt/PCP pathway associated genes in the SCC subtype. Dysregulation of the canonical Wnt pathway, characterized by increased levels of beta-catenin and epigenetic silencing of negative regulators, has been reported in adenocarcinoma of the lung. Our results suggest that SCC and AC utilize different branches of the Wnt pathway during oncogenesis.</text><annotation id="13"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="1066" /><text>beta-catenin</text></annotation><annotation id="14"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="1202" /><text>SCC</text></annotation><annotation id="15"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="972" /><text>SCC</text></annotation><annotation id="16"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="613" /><text>SCC</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1279</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1292</offset><text>Lung cancer is the leading cause of cancer-related death in both men and women throughout the world, and more than fifteen thousand people in the United States die from the disease each year. About 80% of lung cancers are classified as non-small cell lung carcinoma (NSCLC). Adenocarcinoma (AC) and squamous cell carcinoma (SCC) are the two major subtypes of NSCLC, each representing about 40% cases of NSCLC. SCC is characterized as a poorly differentiated tumor subtype that develops in the proximal airways and is strongly associated with cigarette smoking. In contrast, AC usually arises in the peripheral airways and is more commonly observed in non-smokers and women.</text><annotation id="41"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="1616" /><text>SCC</text></annotation><annotation id="42"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="1702" /><text>SCC</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1966</offset><text>High-throughput gene expression analysis has been widely used to study cancer to facilitate the discovery of novel oncogenes and elucidate the mechanism of tumorigenesis. These genome-wide analyses usually result in the identification of hundreds or thousands of genes with an altered expression pattern. However, interpreting the relevance of these long gene lists remains a significant challenge.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2365</offset><text>Several pathway analysis approaches have been developed to uncover the molecular signaling patterns underlying these candidate gene lists. One of the most common approaches is based on statistical enrichment (e.g., hypergeometric distribution with the Fisher's Exact Test). These methods test the gene list of interest for enrichment relative to groups of genes that are known to share a common function. This approach, broadly referred to here as functional group enrichment analysis (FGA), calculates the statistical significance of the overlap with the goal of identifying activated or repressed pathways. This basic method is used in many major pathway analysis tools including Ingenuity, Database for Annotation, Visualization and Integrated Discovery (DAVID), and gene set enrichment analysis (GSEA). These tools have been successfully applied to generate molecular insights in many biological systems.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3274</offset><text>In this study, we analyzed a collection of 138 lung cancer samples using an FGA approach with the goal of defining the active pathways that differentiate the two major sample groups. While developmental and cell cycle pathways were broadly implicated, this approach was unable to identify specific molecular pathways that were amenable to hypothesis testing. In an effort to identify more precise pathways that were dysregulated in this data set, we developed a new algorithm called Coverage Analysis with Fisher's Exact Test (CAFET). This algorithm specifically accounts for the case where dysregulation of even a single pathway member can result in altered pathway signaling. Using the CAFET approach, we found that Wnt pathway components were differentially expressed in SCC samples. Further characterization of these samples revealed an inhibition of the canonical branch of the Wnt pathway, coupled with an enhancement of the non-canonical Wnt PCP signaling cascade. These results suggest that lung SCC uses an alternate branch of the Wnt pathway for survival and development.</text><annotation id="64"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="4278" /><text>SCC</text></annotation><annotation id="65"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="4048" /><text>SCC</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4358</offset><text>Materials and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4380</offset><text>Gene expression data and analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4414</offset><text>Microarray gene expression data from 62 human lung AC and 76 lung SCC were downloaded from NCBI's GEO (GSE8894). Probe sets with a maximum intensity below 100 were removed. Hierarchical clustering was performed with R using a Euclidean distance metric and average linkage. The significance of differential expression for each gene was evaluated using the two primary clusters from the global clustering analysis. The false discovery rate (FDR) was estimated using the Benjamini Hochberg method. Genes were defined as differentially expressed if at least one probe had a FDR&lt;0.05 and a mean difference greater than 2.5-fold between the two groups (Tables S1 and S2).</text><annotation id="71"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="4480" /><text>SCC</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5080</offset><text>Microarray data from a second lung cancer expression study (GSE10245) comprised of 58 NSCLC samples (40 AC and 18 SCC) were also analyzed and processed in the same way as above.</text><annotation id="77"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="5194" /><text>SCC</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5258</offset><text>Functional group enrichment analysis (FGA)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5301</offset><text>Functional gene sets were downloaded from two sources. Human gene annotations were obtained from NCBI's gene2go table (June19, 2009 snapshot from ftp://ftp.ncbi.nih.gov/gene/DATA/gene2go.gz), from which 10102 gene sets were extracted with at least five genes above the maximum intensity threshold in our data set. We also utilized the KEGG metabolic and signaling pathways database, which contained 202 manually-annotated human pathways with the same gene expression threshold (June 19, 2009 snapshot from ftp://ftp.genome.jp/pub/kegg/pathways).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5847</offset><text>In this study, we calculated FGA enrichment using Fisher's exact test and hypergeometric distribution. The p-value for the enrichment of a gene set of NG genes and a functional group of NF genes was calculated by: </text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6064</offset><text>Where NC is defined as the number of genes within the gene set assigned to the functional group, NT is the total number of annotated genes of microarray. The FGA approach is also illustrated schematically in  Figure 1 . FDR was estimated using the Benjamini-Hochberg method, and a threshold of 0.05 was applied.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g001.jpg</infon><infon key="id">pone-0025807-g001</infon><infon key="type">fig_caption_title</infon><offset>6376</offset><text>Schematic illustration of the FGA and CAFET approaches for pathway enrichment.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g001.jpg</infon><infon key="id">pone-0025807-g001</infon><infon key="type">fig_caption</infon><offset>6455</offset><text>Both the FGA and CAFET approaches begin with the same data matrix of gene expression measurements, and both seek to assess the relevance of a particular Functional Gene Set (FGS) (i.e., pathway) in the division of samples into two groups. Red boxes indicate dysregulation of a specific gene in a specific sample. FGA approaches employ a three-step process. In step 1, differentially expressed genes are identified, typically based on a t-test or ANOVA analysis. In step 2, genes with a role the FGS of interest are identified. In step 3, Fisher's exact test is used to test for enrichment of FGS genes among differentially-expressed genes. CAFET employs a similar four-step process. In step 1, FGS genes are first identified and the corresponding sub-matrix is extracted. In step 2, samples are evaluated for the presence of a particular gene expression signature. In this study, the signature is marked as present if one or more pathway genes are dysregulated. In step 3, the division of samples between two groups of interest is defined. In step 4, Fisher's exact test is used to test for enrichment of samples containing the pathway signature among the sample group of interest. In cases where the majority of FGS members are differentially regulated (A), both FGA and CAFET detect a statistically significant relationship between the FGS and the sample grouping. However, in cases where each sample has only a few FGS members dysregulated (B), CAFET but not FGA results in a significant enrichment for the associated FGS.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7985</offset><text>Coverage Analysis with Fisher's Exact Test (CAFET)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8038</offset><text>CAFET calculates the degree to which samples with a desired expression property were concentrated in a particular sample cluster. In this study, the desired property for a single gene in a single sample was its overexpression relative to the median expression across all samples. Like the FGA, the CAFET metric is based on the Fisher's exact test and hypergeometric distribution. However, instead of calculating the enrichment of genes as in FGA, CAFET calculates the enrichment of samples with a certain expression feature.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8565</offset><text>The p-value of CAFET for a single gene is calculated by:where SG is the number of samples in the sample cluster of interest, ST is the total number of samples, SP is the number of samples with the expression pattern of interest, and SC is the number of samples in SP that fall in SG. Our expression filtering criterion focused on expression greater than 2.5-fold of the median expression across of all samples, or on expression less than 0.5 fold of the median. (Asymmetric thresholds were used because the baseline noise limits the magnitude of down-regulation.) For any gene with multiple probes, all those samples with at least one probe reaching the criteria were taken into account. FDR was again estimated using the Benjamini-Hochberg method, and a threshold of 0.05 was applied.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9351</offset><text>A CAFET p-value and FDR can be calculated for a single gene (as described above) or for an entire functional group. In the latter case, the desired property is overexpression of any gene in the functional group (illustrated schematically in  Figure 1 ). For each gene i = 1 ... n in a given functional group, SP(i) and SC(i) were defined as the SC and SP in formula 2. We further defined SFP as the union of samples sets for SP(i) for all gene i, i = 1 ... n, and SFC as the number of union of samples sets for SC(i) for all gene i, 1 ... n. The CAFET p-value of the functional group was then calculated by: </text><annotation id="103"><infon key="identifier">1113</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">976</infon><location length="5" offset="9660" /><text>SP(i)</text></annotation><annotation id="104"><infon key="identifier">1113</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">976</infon><location length="5" offset="9776" /><text>SP(i)</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9968</offset><text>FDR was then estimated as described previously. Only functional groups with at least 5 genes with  were considered.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10084</offset><text>Score of Wnt SCC signature</text><annotation id="107"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="10097" /><text>SCC</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10111</offset><text>To assess the degree to which individual samples exhibited dysregulation of the Wnt pathway, we developed an ad hoc scoring function based on gene expression values. A normalized expression value is calculated for each gene based on the average intensity of all its probes after log2 transformation and standardization. The score of the Wnt SCC signature for any sample is the sum of expression values of upregulated genes subtracting the sum of expression values of down-regulated genes.</text><annotation id="109"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="10452" /><text>SCC</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10600</offset><text>Primary Tumor and Cancer Cell Line Samples</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10643</offset><text>cDNA from 40 lung cancer samples (14 SCC and 26 non-SCC) was obtained from Origene (Rockville, MD; product #HLRT103). Expression of FZD6, DVL3, and WNT5A was interrogated via RT-PCR according to the protocol below.</text><annotation id="120"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="10695" /><text>SCC</text></annotation><annotation id="121"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="10775" /><text>FZD6</text></annotation><annotation id="122"><infon key="identifier">1857</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20928</infon><location length="4" offset="10781" /><text>DVL3</text></annotation><annotation id="123"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="10791" /><text>WNT5A</text></annotation><annotation id="124"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="10680" /><text>SCC</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10858</offset><text>Total RNA from 12 primary human lung tumors and 12 matched normal tissue samples were obtained from Asterand (Detroit, MI). Informed consent was obtained from patients by Asterand under approval from the appropriate IRBs. The samples were handled and maintained according to protocols approved by the IRB of the Genomics Institute of the Novartis Research Foundation (GNF).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11232</offset><text>SCC lung cancer cell lines LK2 (RIKEN, Japan), NCI-H520 (ATCC, Monassas, VA), LUDLU-1 (ECACC, UK) and HARA-1 (HSSRB, Japan) were maintained in HyClone RPMI-1640 medium supplemented with 10% FBS (Thermo Fisher Scientific Inc., Waltham, MA). Non-SCC lung cancer cell lines ABC1 (HSSRB, Japan), PC14 (RIKEN, Japan), NCI-H2342, NCI-H209, A549, NCI-H661, HCC827 and NCI-H522 (ATCC, Monassas, VA) were maintained in the recommended media by their respective cell banks. Trizol reagent (Invitrogen, Carlsbad, CA) was used to extract total RNA from cancer cell lines.</text><annotation id="145"><infon key="identifier">19</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21130</infon><location length="4" offset="11503" /><text>ABC1</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>11792</offset><text>Real-Time PCR Assays</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11813</offset><text>For expression analysis, cDNA was prepared using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). All RT-PCR assays were performed in duplicate using pre-designed gene-specific Taqman probes and Taqman Universal PCR Master Mix (Applied Biosystems, Foster City, CA) on the 7900HT FAST Real-Time PCR System. Relative mRNA expression of target genes was normalized to ACTB expression as an internal amplification control.</text><annotation id="160"><infon key="identifier">60</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">110648</infon><location length="4" offset="12203" /><text>ACTB</text></annotation><annotation id="161"><infon key="identifier">83881</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8445</infon><location length="3" offset="12061" /><text>Mix</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>12257</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12265</offset><text>We analyzed gene expression data from 138 NSCLC samples, classified into 76 SCC and 62 AC tumors. Hierarchical clustering separated the majority of the samples into two branches, which we labeled as simply Group 1 and Group 2. Group 1was primarily comprised of SCC samples (59 SCC, 4AC). Group 2 was further subdivided into Group 2a, which contained only AC samples, and Group 2b, which contained the majority of the remaining SCC samples that were not found in Group 1 ( Figure 2 ). Recognizing that lung cancer is a very heterogeneous disease even within histological classes, we specifically chose to use the global, unsupervised clustering results as the basis for our study. Specifically, we focused on identifying the molecular basis distinguishing Group 1 from Group 2 lung cancer samples.</text><annotation id="170"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="12526" /><text>SCC</text></annotation><annotation id="171"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="12692" /><text>SCC</text></annotation><annotation id="172"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="12542" /><text>SCC</text></annotation><annotation id="173"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="12341" /><text>SCC</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g002.jpg</infon><infon key="id">pone-0025807-g002</infon><infon key="type">fig_caption_title</infon><offset>13062</offset><text>Hierarchical clustering of 138 NSCLC samples reveals two predominant sample clusters.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g002.jpg</infon><infon key="id">pone-0025807-g002</infon><infon key="type">fig_caption</infon><offset>13148</offset><text>Hierarchical clustering was performed based on log-transformed expression data using Euclidean distance and average linkage. The brown branches of the tree were labeled "Group 1", and the light blue cluster was labeled "Group 2". Group 2 was further subdivided into Group 2a (dark blue) and Group 2b (red).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13463</offset><text>We identified 635 genes with significantly higher expression in Group 1 (Table S1), and 740 genes with significantly higher expression in Group 2 (Table S2). To identify relevant pathways in these gene lists, we applied FGA analysis to these sets of genes. We found that genes overexpressed in Group 1 were enriched in functional groups related to cell cycle and development (Table S3), while genes overexpressed in Group 2 had significant association with many immune response functional groups (Table S4).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13971</offset><text>Enrichment in functional groups related to cell cycle and development was expected given their known roles in oncogenesis and metastasis. However, the functional gene groups identified in this analysis often contained hundreds or thousands of genes, and as a result, the formulation of specific mechanistic hypotheses proved difficult. Enrichment scores of more specific signaling pathways using FGA were not statistically significant, and varying filtering criteria for differential expression did not result in any improvement.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14501</offset><text>We hypothesized that this lack of specificity was a fundamental property of the enrichment analysis underlying FGA. Specifically, the FGA approach is designed to detect pathways in which multiple pathway genes are differentially expressed, and more significant p-values are achieved when more pathway genes are differentially expressed ( Figure 1 ). The first step in FGA is the identification of differentially expressed genes, typically involving a statistical measure like a t-test or ANOVA. The second step involves identifying the set of pathway genes for a pathway of interest, and third step tests the enrichment of pathway genes among differentially expressed genes. This procedure is quite effective when the majority of pathway genes are differentially expressed in each case sample studied ( Figure 1A ).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15317</offset><text>However, dysregulation of even a single pathway gene is often sufficient to result in altered pathway signaling. Consider a study in which all case samples have altered pathway activity, but where each sample has a different pathway member dysregulated ( Figure 1B ). In this case, FGA will not detect the importance of the altered pathway.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15658</offset><text>To address this limitation, we developed a complementary algorithm called Coverage Analysis with Fisher's Exact Test (CAFET). In the first step, data for pathway members are extracted from the gene expression matrix. In the second key step, CAFET identifies samples with a relevant gene expression signature, which in our case can be defined by the dysregulation of as few as one pathway member. The third step defines the clinically relevant sample groups (e.g., case versus control, or SCC versus AC). And the fourth step tests the enrichment of dysregulated samples among the sample groups using the same Fisher's exact test as in FGA ( Figure 1 ). The CAFET procedure is sensitive to data sets in which the majority of pathway members are dysregulated ( Figure 1A ), as well less obvious cases in which only one or a few pathway members are dysregulated ( Figure 1B ). In contrast to FGA where more significant p-values are achieved when more pathway genes are differentially expressed, CAFET reports more significant p-values when more samples have at least one differentially expressed pathway member.</text><annotation id="182"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="16146" /><text>SCC</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16770</offset><text>We used CAFET to identify functional groups which significantly differentiated Group 1 from Group 2. Consistent with the FGA analysis, Group 1 samples showed significant CAFET enrichment for many developmental process related functional groups ( Table 1  ; full results in Tables S5 and S6). As designed, this list also included specific enriched molecular pathways. The Wnt receptor activity pathway (GO:0042813) was among the most enriched functional groups (p = 8.55E-13, FDR = 7.94E-11), with ninety lung cancer samples expressing at least one of the following seven components (FZD3; FZD4; FZD6; FZD7; FZD8; FZD10; RYK) at least 2.5-fold above the average of Group 2 samples. Sixty of these ninety samples were found to cluster with Group 1, indicating a strong association of the Wnt pathway. Given the known roles for Wnt signaling in oncogenesis and metastasis, we focused our study on the Wnt pathway to further investigate its potential dysregulation in the two main NSCLC subtypes.</text><annotation id="193"><infon key="identifier">7976</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">23004</infon><location length="4" offset="17353" /><text>FZD3</text></annotation><annotation id="194"><infon key="identifier">8322</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7325</infon><location length="4" offset="17359" /><text>FZD4</text></annotation><annotation id="195"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="17365" /><text>FZD6</text></annotation><annotation id="196"><infon key="identifier">8324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20751</infon><location length="4" offset="17371" /><text>FZD7</text></annotation><annotation id="197"><infon key="identifier">8325</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">40606</infon><location length="4" offset="17377" /><text>FZD8</text></annotation><annotation id="198"><infon key="identifier">11211</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21411</infon><location length="5" offset="17383" /><text>FZD10</text></annotation><annotation id="199"><infon key="identifier">6259</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68287</infon><location length="3" offset="17390" /><text>RYK</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>17775</offset><text>: number of genes in the functional group with at least one overexpressed sample.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>17857</offset><text>: the total number of samples overexpressing at least one gene in the functional group (out of 138 samples total).</text></passage><passage><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>17972</offset><text>: the number of Group 1 samples overexpressing at least one gene in the functional group (out of 63 samples in Group 1).</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">pone-0025807-t001.xml</infon><infon key="id">pone-0025807-t001</infon><infon key="type">table_caption_title</infon><offset>18093</offset><text>Most significant functional groups identified by CAFET based on genes overexpressed in Group 1 samples.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="id">pone-0025807-t001</infon><infon key="type">table</infon><infon key="File">pone-0025807-t001.xml</infon><offset>18197</offset><text>FG_ID FG_Name Gene No.a  Total No.(138)b  G1 No. (63)c  G1_pValue G1 FDR GO:0030299 intestinal cholesterol absorption 5 79 60 2.08E-18 1.02E-15 hsa03030 DNA replication - Homo sapiens (human) 33 87 62 1.58E-17 5.08E-15 GO:0001840 neural plate development 5 70 55 3.93E-16 9.87E-14 GO:0000777 condensed chromosome kinetochore 40 92 62 4.92E-15 8.75E-13 GO:0005663 DNA replication factor C complex 6 57 48 5.43E-15 9.48E-13 GO:0048854 brain morphogenesis 7 77 57 6.03E-15 1.02E-12 GO:0033170 protein-DNA loading ATPase activity 5 56 47 2.35E-14 3.37E-12 GO:0003689 DNA clamp loader activity 5 56 47 2.35E-14 3.37E-12 GO:0006297 nucleotide-excision repair, DNA gap filling 17 81 58 2.95E-14 4.10E-12 GO:0048048 embryonic eye morphogenesis 7 76 56 3.98E-14 5.47E-12 GO:0035058 sensory cilium assembly 5 59 48 1.13E-13 1.39E-11 GO:0000779 condensed chromosome, centromeric region 43 95 62 1.17E-13 1.40E-11 GO:0007618 mating 5 80 57 2.06E-13 2.44E-11 GO:0051588 regulation of neurotransmitter transport 5 92 61 2.24E-13 2.60E-11 GO:0046928 regulation of neurotransmitter secretion 5 92 61 2.24E-13 2.60E-11 GO:0030057 desmosome 19 101 63 6.46E-13 6.17E-11 hsa03430 Mismatch repair - Homo sapiens (human) 21 84 58 8.22E-13 7.77E-11 GO:0006596 polyamine biosynthetic process 5 49 42 8.37E-13 7.84E-11 GO:0042813 Wnt receptor activity 7 90 60 8.55E-13 7.94E-11 GO:0005657 replication fork 28 97 62 8.74E-13 7.97E-11 GO:0002347 response to tumor cell 5 97 62 8.74E-13 7.97E-11 GO:0070567 cytidylyltransferase activity 6 52 43 5.09E-12 3.98E-10 GO:0005871 kinesin complex 12 73 53 5.85E-12 4.47E-10 GO:0031507 heterochromatin formation 5 73 53 5.85E-12 4.47E-10 GO:0008088 axon cargo transport 10 92 60 6.36E-12 4.78E-10 GO:0042490 mechanoreceptor differentiation 9 92 60 6.36E-12 4.78E-10 GO:0042491 auditory receptor cell differentiation 6 71 52 8.50E-12 6.30E-10 GO:0050892 intestinal absorption 8 96 61 1.19E-11 8.76E-10 </text><annotation id="211"><infon key="identifier">1769</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1049</infon><location length="6" offset="18707" /><text>ATPase</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20225</offset><text>We first expanded our list of Wnt pathway members to 172 genes in nine Wnt-related functional groups (Tables S7 and S8), and then applied CAFET on a gene-by-gene basis, testing whether samples with substantially altered expression were enriched among the SCC-dominated Group 1. This approach identified 53 genes that displayed differential expression and could be associated specifically with the Group 1 cluster ( Table 2 ). Of these 53 genes, 34 were observed to be strongly up-regulated in Group 1, while 19 displayed significantly reduced expression levels. According to the CAFET method, SOX2 was the most significantly enriched gene in the SCC cluster (FDR = 3.86E-18), with eighty eight percent of samples with high SOX2 expression (54 of 61) clustering to Group 1. SOX2 has recently been identified as a lineage survival oncogene in lung and esophageal squamous carcinoma.</text><annotation id="226"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="20480" /><text>SCC</text></annotation><annotation id="227"><infon key="identifier">6657</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68298</infon><location length="4" offset="20818" /><text>SOX2</text></annotation><annotation id="228"><infon key="identifier">6657</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68298</infon><location length="4" offset="20948" /><text>SOX2</text></annotation><annotation id="229"><infon key="identifier">6657</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68298</infon><location length="4" offset="20998" /><text>SOX2</text></annotation><annotation id="230"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="20871" /><text>SCC</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21112</offset><text>: number of samples with high expression.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21154</offset><text>: number of Group 1 samples with high expression.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21204</offset><text>: number of samples with low expression.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>21245</offset><text>: number of Group 1 samples with low expression.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">pone-0025807-t002.xml</infon><infon key="id">pone-0025807-t002</infon><infon key="type">table_caption_title</infon><offset>21294</offset><text>Genes in the Wnt pathway with significant CAFET enrichment.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="id">pone-0025807-t002</infon><infon key="type">table</infon><infon key="File">pone-0025807-t002.xml</infon><offset>21354</offset><text>Up-regulation   Down-regulation   Gene Total Noa  G1 Nob  G1_FDR Gene Total Noc  G1 Nod  G1_FDR SOX2 61 54 3.86E-18 TLE2 39 33 2.94E-07 FZD10 60 53 1.67E-17 FZD5 35 28 6.08E-05 VANGL2 42 41 1.98E-15 CTBP1 21 19 0.000138 FZD7 46 42 4.62E-13 MAPK9 23 19 0.001634 PRKX 37 36 8.23E-13 ILK 11 11 0.001858 PRKY 39 37 2.82E-12 CAMK2D 51 34 0.002322 CELSR2 41 38 7.28E-12 FRZB 32 24 0.002315 WNT5A 38 36 8.82E-12 PRKCA 35 25 0.005208 TBL1XR1 35 33 2.49E-10 PPAP2B 37 26 0.00568 DVL3 27 27 8.30E-10 CCND1 39 27 0.00611 SLC9A3R1 30 29 1.69E-09 FZD8 27 20 0.010784 TBL1X 42 35 1.10E-07 SFRP4 52 33 0.011249 WNT2B 21 21 3.05E-07 PRKCB 35 24 0.016357 SOSTDC1 46 36 1.48E-06 CCND3 19 15 0.018143 SENP2 26 24 1.69E-06 MMP7 43 28 0.018448 CSNK2A1 20 19 1.98E-05 TGFB1I1 23 17 0.027185 RYK 20 19 1.98E-05 PPP3CA 18 14 0.031241 FZD6 16 16 2.66E-05 SKP1 33 22 0.042493 MYC 25 21 0.000348 DIXDC1 22 16 0.044592 SMAD3 29 23 0.000702     FOSL1 44 31 0.001016     KREMEN1 24 19 0.003803     HHEX 26 20 0.00483     TP53 9 9 0.007524     WNT11 9 9 0.007524     PLCB4 34 24 0.008865     SMAD2 12 11 0.009335     TLE1 17 14 0.013585     DVL2 8 8 0.015954     RNF138 11 10 0.018424     VANGL1 11 10 0.018424     BARX1 21 16 0.02324     LEF1 16 13 0.024639     LDB1 10 9 0.035772     </text><annotation id="274"><infon key="identifier">7089</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20693</infon><location length="4" offset="21470" /><text>TLE2</text></annotation><annotation id="275"><infon key="identifier">11211</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21411</infon><location length="5" offset="21490" /><text>FZD10</text></annotation><annotation id="276"><infon key="identifier">57216</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">62161</infon><location length="6" offset="21531" /><text>VANGL2</text></annotation><annotation id="277"><infon key="identifier">1487</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1015</infon><location length="5" offset="21553" /><text>CTBP1</text></annotation><annotation id="278"><infon key="identifier">5601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55685</infon><location length="5" offset="21594" /><text>MAPK9</text></annotation><annotation id="279"><infon key="identifier">817</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55561</infon><location length="6" offset="21674" /><text>CAMK2D</text></annotation><annotation id="280"><infon key="identifier">1952</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1078</infon><location length="6" offset="21696" /><text>CELSR2</text></annotation><annotation id="281"><infon key="identifier">79718</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">69382</infon><location length="7" offset="21780" /><text>TBL1XR1</text></annotation><annotation id="282"><infon key="identifier">8613</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">15410</infon><location length="6" offset="21803" /><text>PPAP2B</text></annotation><annotation id="283"><infon key="identifier">595</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1334</infon><location length="5" offset="21844" /><text>CCND1</text></annotation><annotation id="284"><infon key="identifier">9368</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3137</infon><location length="8" offset="21864" /><text>SLC9A3R1</text></annotation><annotation id="285"><infon key="identifier">6907</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4128</infon><location length="5" offset="21908" /><text>TBL1X</text></annotation><annotation id="286"><infon key="identifier">25928</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">9154</infon><location length="7" offset="21992" /><text>SOSTDC1</text></annotation><annotation id="287"><infon key="identifier">1457</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">90874</infon><location length="7" offset="22077" /><text>CSNK2A1</text></annotation><annotation id="288"><infon key="identifier">7041</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7572</infon><location length="7" offset="22100" /><text>TGFB1I1</text></annotation><annotation id="289"><infon key="identifier">6500</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38775</infon><location length="4" offset="22184" /><text>SKP1</text></annotation><annotation id="290"><infon key="identifier">85458</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">82369</infon><location length="6" offset="22223" /><text>DIXDC1</text></annotation><annotation id="291"><infon key="identifier">8061</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3967</infon><location length="5" offset="22270" /><text>FOSL1</text></annotation><annotation id="292"><infon key="identifier">83999</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12935</infon><location length="7" offset="22295" /><text>KREMEN1</text></annotation><annotation id="293"><infon key="identifier">81839</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">44540</infon><location length="6" offset="22512" /><text>VANGL1</text></annotation><annotation id="294"><infon key="identifier">56033</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7241</infon><location length="5" offset="22538" /><text>BARX1</text></annotation><annotation id="295"><infon key="identifier">51176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7813</infon><location length="4" offset="22562" /><text>LEF1</text></annotation><annotation id="296"><infon key="identifier">6424</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2267</infon><location length="5" offset="21929" /><text>SFRP4</text></annotation><annotation id="297"><infon key="identifier">6259</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68287</infon><location length="3" offset="22123" /><text>RYK</text></annotation><annotation id="298"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="21738" /><text>WNT5A</text></annotation><annotation id="299"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="22164" /><text>FZD6</text></annotation><annotation id="300"><infon key="identifier">8325</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">40606</infon><location length="4" offset="21888" /><text>FZD8</text></annotation><annotation id="301"><infon key="identifier">8324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20751</infon><location length="4" offset="21574" /><text>FZD7</text></annotation><annotation id="302"><infon key="identifier">7855</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2590</infon><location length="4" offset="21511" /><text>FZD5</text></annotation><annotation id="303"><infon key="identifier">7482</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22526</infon><location length="5" offset="21950" /><text>WNT2B</text></annotation><annotation id="304"><infon key="identifier">1856</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20927</infon><location length="4" offset="22464" /><text>DVL2</text></annotation><annotation id="305"><infon key="identifier">1857</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20928</infon><location length="4" offset="21824" /><text>DVL3</text></annotation><annotation id="306"><infon key="identifier">896</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20419</infon><location length="5" offset="22015" /><text>CCND3</text></annotation><annotation id="307"><infon key="identifier">5578</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55679</infon><location length="5" offset="21759" /><text>PRKCA</text></annotation><annotation id="308"><infon key="identifier">59343</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11005</infon><location length="5" offset="22036" /><text>SENP2</text></annotation><annotation id="309"><infon key="identifier">7481</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20970</infon><location length="5" offset="22367" /><text>WNT11</text></annotation><annotation id="310"><infon key="identifier">3611</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3318</infon><location length="3" offset="21635" /><text>ILK</text></annotation><annotation id="311"><infon key="identifier">2487</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1126</infon><location length="4" offset="21718" /><text>FRZB</text></annotation><annotation id="312"><infon key="identifier">7088</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21058</infon><location length="4" offset="22440" /><text>TLE1</text></annotation><annotation id="313"><infon key="identifier">6657</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68298</infon><location length="4" offset="21450" /><text>SOX2</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22650</offset><text>More detailed analysis of these genes revealed that the direction of altered expression seemed to indicate an up-regulation of the non-canonical Wnt/PCP pathway and down-regulation of the canonical Wnt/beta-catenin signaling branch in Group 1 samples ( Figure 3  and  Table 2 ). Several of these findings are summarized here:</text><annotation id="315"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="22852" /><text>beta-catenin</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g003.jpg</infon><infon key="id">pone-0025807-g003</infon><infon key="type">fig_caption_title</infon><offset>22976</offset><text>Mapping gene expression changes on the Wnt pathway revealed strong upregulation of PCP signaling and downregulation of canonical signaling.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g003.jpg</infon><infon key="id">pone-0025807-g003</infon><infon key="type">fig_caption</infon><offset>23116</offset><text>The three branches of Wnt signaling are shown -calcium (pink background), beta-catenin (green background), and PCP (blue background). Up/down arrows indicate overexpression and downregulation, respectively, in Group 1 samples. Genes whose expression change is consistent with canonical pathway inhibition and PCP pathway activation are colored red. Those genes promoting canonical signaling and inhibiting the PCP branch are colored green. Genes with no significant change in expression, or whose expression change has no selectivity between the canonical and non-canonical branches are colored white. The down-regulation of CAMK2D and PRKCA (dark blue) acts to inhibit Wnt Ca2+ signaling.</text><annotation id="323"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="23190" /><text>beta-catenin</text></annotation><annotation id="324"><infon key="identifier">817</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55561</infon><location length="6" offset="23741" /><text>CAMK2D</text></annotation><annotation id="325"><infon key="identifier">5578</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55679</infon><location length="5" offset="23752" /><text>PRKCA</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23808</offset><text>- Four genes (RYK, CELSR2, VANGL1, VANGL2) described as upstream, positive regulators of the Wnt/PCP pathway were all enriched by CAFET in Group 1 samples.</text><annotation id="334"><infon key="identifier">6259</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68287</infon><location length="3" offset="23822" /><text>RYK</text></annotation><annotation id="335"><infon key="identifier">1952</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1078</infon><location length="6" offset="23827" /><text>CELSR2</text></annotation><annotation id="336"><infon key="identifier">81839</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">44540</infon><location length="6" offset="23835" /><text>VANGL1</text></annotation><annotation id="337"><infon key="identifier">57216</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">62161</infon><location length="6" offset="23843" /><text>VANGL2</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23964</offset><text>- Two Wnt ligands, WNT5A and WNT11 , were also found overexpressed in Group 1 samples. Both of these Wnt ligands are known to enhance the non-canonical branch of the Wnt pathway while inhibiting the canonical signaling cascade. Of the 38 samples overexpressing WNT5A, 37 were found in Group 1. Similarly all nine samples overexpressing WNT11 were Group 1 samples.</text><annotation id="342"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="23983" /><text>WNT5A</text></annotation><annotation id="343"><infon key="identifier">7481</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20970</infon><location length="5" offset="23993" /><text>WNT11</text></annotation><annotation id="344"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="24225" /><text>WNT5A</text></annotation><annotation id="345"><infon key="identifier">7481</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20970</infon><location length="5" offset="24300" /><text>WNT11</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24328</offset><text>- The Frizzled receptor FZD6 was exclusively overexpressed among Group 1 samples. This gene was reported to repress canonical Wnt signaling and to activate the non-canonical Wnt pathway.</text><annotation id="347"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="24352" /><text>FZD6</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24515</offset><text>- Samples overexpressing two LRP6 inhibitors, SOSTC1 and KREMEN1, were enriched among Group 1 samples. The LRP6 co-receptor is required for canonical Wnt signaling, but not non-canonical signaling.</text><annotation id="351"><infon key="identifier">4040</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1747</infon><location length="4" offset="24544" /><text>LRP6</text></annotation><annotation id="352"><infon key="identifier">83999</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12935</infon><location length="7" offset="24572" /><text>KREMEN1</text></annotation><annotation id="353"><infon key="identifier">4040</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1747</infon><location length="4" offset="24622" /><text>LRP6</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24713</offset><text>- DIXDC1 was down-regulated in 21 samples, 16 of which were in Group 1. This gene functions as a switch by enhancing canonical Wnt signaling while inhibiting non-canonical Wnt signaling.</text><annotation id="355"><infon key="identifier">85458</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">82369</infon><location length="6" offset="24715" /><text>DIXDC1</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24900</offset><text>- Upregulation of SENP2, accompanied by reduced expression of ILK in Group 1, indicated a potential increase in beta-catenin degradation and inhibition of the canonical signaling cascade.</text><annotation id="359"><infon key="identifier">59343</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">11005</infon><location length="5" offset="24918" /><text>SENP2</text></annotation><annotation id="360"><infon key="identifier">3611</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3318</infon><location length="3" offset="24962" /><text>ILK</text></annotation><annotation id="361"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="25012" /><text>beta-catenin</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>25088</offset><text>Among all the changes in the Wnt pathway, there were only three changes that specifically indicated a potential activation in canonical signaling: increased expression of WNT2B, and the down-regulation of FRZB and SKP1 . In contrast, 12 of the observed changes were consistent with the activation of the non-canonical Wnt pathway or inhibition of the canonical signaling branch. Interestingly, we also saw a decrease expression of CAMK2D and PRKCA, two components mediating the Wnt/Ca2+ pathway.</text><annotation id="368"><infon key="identifier">7482</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22526</infon><location length="5" offset="25259" /><text>WNT2B</text></annotation><annotation id="369"><infon key="identifier">2487</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1126</infon><location length="4" offset="25293" /><text>FRZB</text></annotation><annotation id="370"><infon key="identifier">6500</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">38775</infon><location length="4" offset="25302" /><text>SKP1</text></annotation><annotation id="371"><infon key="identifier">817</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55561</infon><location length="6" offset="25519" /><text>CAMK2D</text></annotation><annotation id="372"><infon key="identifier">5578</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55679</infon><location length="5" offset="25530" /><text>PRKCA</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>25584</offset><text>These results support the model of increased Wnt/PCP signaling and decreased canonical Wnt signaling in Group 1 SCC samples (  Figure 4 ). To test the generality of these findings, we examined the role of the Wnt pathway in multiple independent data sets. First, we tested whether the Wnt/PCP signature could be validated in a second, independent gene expression data set and scored the 58 NSCLC samples (40 ACC and 18 SCC) according to the differential expression of genes listed in  Table 2 . Samples with high Wnt/PCP scores were strongly enriched for SCC subtype ( Figure 5A ), confirming a general association between SCC and Wnt/PCP signaling in primary lung tumor sample datasets.</text><annotation id="380"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="26139" /><text>SCC</text></annotation><annotation id="381"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="26207" /><text>SCC</text></annotation><annotation id="382"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="26003" /><text>SCC</text></annotation><annotation id="383"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="25696" /><text>SCC</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g004.jpg</infon><infon key="id">pone-0025807-g004</infon><infon key="type">fig_caption_title</infon><offset>26272</offset><text>Differential expression pattern of Wnt signature genes in lung cancer samples.</text></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g004.jpg</infon><infon key="id">pone-0025807-g004</infon><infon key="type">fig_caption</infon><offset>26351</offset><text>Each column represents one of the 138 lung cancer samples as ordered in Fig 1. SCC samples are colored brown and AC samples are colored blue. Each row represents a Wnt pathway gene in Table 2, ranked according to p-value. Red and blue cells indicate overexpression and down-regulation, respectively, of individual genes in specific samples.</text><annotation id="390"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="26430" /><text>SCC</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g005.jpg</infon><infon key="id">pone-0025807-g005</infon><infon key="type">fig_caption_title</infon><offset>26692</offset><text>Confirmation of Wnt/PCP signature in SCC of lung.</text><annotation id="393"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="26729" /><text>SCC</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">pone.0025807.g005.jpg</infon><infon key="id">pone-0025807-g005</infon><infon key="type">fig_caption</infon><offset>26742</offset><text>A) Activation of Wnt/PCP signaling in SCC of lung was confirmed in a second independent expression data set. Samples from an additional lung cancer data set were also evaluated for Wnt/PCP signaling using the same scoring system applied to the initial data set. Results showed a strong enrichment of SCC among high-scoring samples. B) Quantitative PCR was also done on three Wnt pathway genes (FZD6, DVL3, WNT5A) in 40 commercially-obtained lung cancer samples. The expression of WNT5A and FZD6were significantly higher in SCC samples. C) RT-PCR confirmed overexpression of Wnt pathway components in SCC of lung. The expression of nine genes in the Wnt pathway was measured in 12 SCC and 12 non-SCC lung samples. All expression measurements were relative to matched normal lung samples. These data showed consistent upregulation in SCC relative to non-SCC samples. Actin was used as a control for normalization.</text><annotation id="409"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27042" /><text>SCC</text></annotation><annotation id="410"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="27136" /><text>FZD6</text></annotation><annotation id="411"><infon key="identifier">1857</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20928</infon><location length="4" offset="27142" /><text>DVL3</text></annotation><annotation id="412"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="27148" /><text>WNT5A</text></annotation><annotation id="413"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="27222" /><text>WNT5A</text></annotation><annotation id="414"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="27232" /><text>FZD6</text></annotation><annotation id="415"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27594" /><text>SCC</text></annotation><annotation id="416"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27574" /><text>SCC</text></annotation><annotation id="417"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27437" /><text>SCC</text></annotation><annotation id="418"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27422" /><text>SCC</text></annotation><annotation id="419"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27342" /><text>SCC</text></annotation><annotation id="420"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27265" /><text>SCC</text></annotation><annotation id="421"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="26780" /><text>SCC</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>27654</offset><text>Next, we performed quantitative PCR on three Wnt pathway genes (FZD6, DVL3, WNT5A) in a commercial panel of 40 lung cancer samples (Origene; Rockville, MD). Although the overexpression of DVL3 did not achieve statistical significance (p = 0.057), FZD6 and WNT5A were both significantly overexpressed in SCC samples relative to the non-SCC samples (p = 0.00056 and p = 0.0011, respectively) ( Figure 5B ).</text><annotation id="433"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="27718" /><text>FZD6</text></annotation><annotation id="434"><infon key="identifier">1857</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20928</infon><location length="4" offset="27724" /><text>DVL3</text></annotation><annotation id="435"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="27730" /><text>WNT5A</text></annotation><annotation id="436"><infon key="identifier">1857</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20928</infon><location length="4" offset="27842" /><text>DVL3</text></annotation><annotation id="437"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="27901" /><text>FZD6</text></annotation><annotation id="438"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="27910" /><text>WNT5A</text></annotation><annotation id="439"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27989" /><text>SCC</text></annotation><annotation id="440"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="27957" /><text>SCC</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>28071</offset><text>In a third validation set, we examined a set of freshly obtained primary lung SCC and AC samples (Asterand; Detroit, MI). We probed the expression of nine representative genes of the Wnt/PCP signature (WNT5A, VANGL2, CELSR2, RYK, DVL3, FZD5, FZD6, FZD7 and FZD10) using real time RT-PCR ( Figure 5C ). With the exception of FZD5, we observed significantly increased expression of the Wnt/PCP components in SCC tumors relative to their matched controls, and also relative to the AC samples.</text><annotation id="454"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="28273" /><text>WNT5A</text></annotation><annotation id="455"><infon key="identifier">57216</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">62161</infon><location length="6" offset="28280" /><text>VANGL2</text></annotation><annotation id="456"><infon key="identifier">1952</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1078</infon><location length="6" offset="28288" /><text>CELSR2</text></annotation><annotation id="457"><infon key="identifier">6259</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68287</infon><location length="3" offset="28296" /><text>RYK</text></annotation><annotation id="458"><infon key="identifier">1857</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20928</infon><location length="4" offset="28301" /><text>DVL3</text></annotation><annotation id="459"><infon key="identifier">7855</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2590</infon><location length="4" offset="28307" /><text>FZD5</text></annotation><annotation id="460"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="28313" /><text>FZD6</text></annotation><annotation id="461"><infon key="identifier">8324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20751</infon><location length="4" offset="28319" /><text>FZD7</text></annotation><annotation id="462"><infon key="identifier">11211</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21411</infon><location length="5" offset="28328" /><text>FZD10</text></annotation><annotation id="463"><infon key="identifier">7855</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2590</infon><location length="4" offset="28395" /><text>FZD5</text></annotation><annotation id="464"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="28149" /><text>SCC</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>28561</offset><text>To determine if the observed WNT/PCP pathway enrichment would translate from in vivo primary samples to in vitro SCC cell line models, we examined expression of eight differentially expressed genes in four SCC lung cancer cell lines: HARA-1, LK2, NCI-H520 and LUDLU-1. Expression of five of the eight genes (WNT5A, RYK, DVL3, FZD6, and FZD10) was significantly up-regulated in the four SCC cell line samples relative to the eight non-SCC NSCLC controls (Figure S1). These cell lines may offer convenient tools to further investigate the role of the Wnt/PCP signature in SCC, as well as provide models for validation of select Wnt/PCP genes as potential therapeutic targets for SCC progression and metastasis.</text><annotation id="479"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="28869" /><text>WNT5A</text></annotation><annotation id="480"><infon key="identifier">6259</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68287</infon><location length="3" offset="28876" /><text>RYK</text></annotation><annotation id="481"><infon key="identifier">1857</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20928</infon><location length="4" offset="28881" /><text>DVL3</text></annotation><annotation id="482"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="28887" /><text>FZD6</text></annotation><annotation id="483"><infon key="identifier">11211</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21411</infon><location length="5" offset="28897" /><text>FZD10</text></annotation><annotation id="484"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="29131" /><text>SCC</text></annotation><annotation id="485"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="29238" /><text>SCC</text></annotation><annotation id="486"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="28995" /><text>SCC</text></annotation><annotation id="487"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="28947" /><text>SCC</text></annotation><annotation id="488"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="28674" /><text>SCC</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>29270</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29281</offset><text>Pathway analysis algorithms are aimed at calculating the statistical significance of gene expression changes in order to identify known biological pathways most affected by the observed changes. FGA implicitly assumes that a majority of genes in a pathway need to be overexpressed to activate the pathway. However, dysregulation of one or two genes is often enough to significantly alter cell signaling, and we developed the CAFET algorithm based on this underlying assumption.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29759</offset><text>By comparison to more well-known FGA enrichment methods, the CAFET approach offers complementary strengths and weaknesses. The statistical power of Fisher's exact test is highly dependent on the total number of observations being compared. Since FGA tests enrichment along a gene axis, it is most appropriate when the number of genes in a pathway is large but can tolerate a relatively small number of samples. In contrast, CAFET performs enrichment along the sample axis, so statistical power is most dependent on the number of samples being studied. CAFET therefore would not be appropriate when the samples sizes are small. However, when samples sizes are large as in the lung cancer data set examined here, CAFET can accurately interrogate gene sets with relatively few genes that are typically characteristic of specific molecular pathways. Based on these characteristics, it is not surprising that CAFET identified the role of the Wnt pathway in our study while FGA did not. Like other variants of gene set enrichment analysis, we believe the CAFET approach will be broadly applicable to pathway enrichment analysis in other large data sets as well.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>30917</offset><text>Many previous studies have explored genomic differences in lung cancer subclasses based on histological distinctions, including differences between AC and SCC (for example). However, in this study, we instead chose to use the results of global, hierarchical clustering of gene expression data to define the comparison groups, effectively stratifying samples based on a molecular rather than histological profile. This approach split the SCC samples into two subclasses, one of which showed greater molecular similarity to AC.</text><annotation id="497"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="31072" /><text>SCC</text></annotation><annotation id="498"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="31354" /><text>SCC</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31443</offset><text>The division of samples based on global hierarchical clustering led to the initial identification by CAFET of the Wnt pathway's importance in lung cancer. Although CAFET also detected the Wnt pathway as being statistically enriched when simply comparing SCC to AC (data not shown), the subset of SCC in Group 2b was clearly more similar to the AC samples in Group 2a than the remaining SCC samples in Group 1.</text><annotation id="504"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="31739" /><text>SCC</text></annotation><annotation id="505"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="31829" /><text>SCC</text></annotation><annotation id="506"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="31697" /><text>SCC</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31855</offset><text>Previous reports using gene expression profiling have also noted genomic similarities between AC and certain subsets of SCC. Interestingly, Wilkerson et al. previously characterized a "secretory" subclass of SCC which overexpressed thyroid transcription factor 1 (NKX2-1/TTF1), the corresponding protein of which is also highly expressed in AC. In the current study, NKX2-1/TTF1 also showed significantly higher expression in Group 2 relative to Group 1 samples (p = 1.55E-31), as well as significantly higher expression in Group 2b relative to Group 1 (p = 1.12E-10). These results reinforce the value of studying differences between groups based on genomic profiling rather than histological classification.</text><annotation id="515"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="31975" /><text>SCC</text></annotation><annotation id="516"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="32063" /><text>SCC</text></annotation><annotation id="517"><infon key="identifier">7080</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2488</infon><location length="30" offset="32087" /><text>thyroid transcription factor 1</text></annotation><annotation id="518"><infon key="identifier">7080</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2488</infon><location length="6" offset="32119" /><text>NKX2-1</text></annotation><annotation id="519"><infon key="identifier">7270</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">135863</infon><location length="4" offset="32126" /><text>TTF1</text></annotation><annotation id="520"><infon key="identifier">7080</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2488</infon><location length="6" offset="32222" /><text>NKX2-1</text></annotation><annotation id="521"><infon key="identifier">7270</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">135863</infon><location length="4" offset="32229" /><text>TTF1</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32581</offset><text>Having used the CAFET method to identify a strong enrichment of the Wnt pathway components in NSCLC, we then pursued more detailed characterization. Specifically, we observed a selective up-regulation of the Wnt/PCP pathway, accompanied by potential silencing of the canonical Wnt signaling branch in the SCC subtype. Although the CAFET approach is only applicable in large data sets with many cancer samples, these results demonstrate that CAFET is a powerful and complementary tool for pathway analysis.</text><annotation id="528"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="32886" /><text>SCC</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>33087</offset><text>The Wnt pathway is highly evolutionarily conserved. Its signaling is initiated by the binding of an extracellular Wnt ligand to a Frizzled-family receptor at the cell surface. Dependent on the specific combination of Wnt/Frizzled isoforms and the presence of specific downstream components, this binding event can signal through three different intracellular branches: the canonical Wnt pathway which terminates in beta-catenin-mediated transcription, the Wnt calcium pathway which results in calcium-dependent signaling, and Wnt planar-cell-polarity (PCP) pathway which modulates cytoskeletal dynamics. The latter two are also referred to as non-canonical Wnt pathways.</text><annotation id="537"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="33502" /><text>beta-catenin</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>33758</offset><text>The function of Wnt signaling in healthy adult lung is unclear, however it is hypothesized to play a role in the maintenance of the stem cell niche in the proximal and distal airways. In addition, several groups have linked hyperactivation of Wnt signaling to oncogenesis and metastasis, through dysregulation of such cell processes as cell proliferation, self-renewal capacity, differentiation and cell movement.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>34172</offset><text>The canonical branch of the Wnt pathway is by far the most thoroughly studied, and has been demonstrated to play a critical role in a wide range of cancers. In colorectal cancer, mutations of beta-catenin, APC, and Axin increase the stability of beta-catenin, leading to the overexpression of downstream targets and promoting cell proliferation and regulate cell differentiation. Dysregulation of canonical Wnt signaling has also been demonstrated in lung cancer, mediated through epigenetic silencing of negative regulators such as SFRP1 and WIF-1  or rare mutations in APC and beta-catenin. In addition, exposure to cigarette smoke activates the canonical Wnt pathway in human bronchial epithelial cells and induces a tumor-like phenotype. Hyperactivation of the canonical Wnt pathway was also observed in metastatic AC subpopulations and demonstrated to be important for AC metastasis to brain and bone.</text><annotation id="553"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="34364" /><text>beta-catenin</text></annotation><annotation id="554"><infon key="identifier">8312</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2614</infon><location length="4" offset="34387" /><text>Axin</text></annotation><annotation id="555"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="34418" /><text>beta-catenin</text></annotation><annotation id="556"><infon key="identifier">6422</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2266</infon><location length="5" offset="34705" /><text>SFRP1</text></annotation><annotation id="557"><infon key="identifier">11197</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31430</infon><location length="5" offset="34715" /><text>WIF-1</text></annotation><annotation id="558"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="34751" /><text>beta-catenin</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>35079</offset><text>The non-canonical Wnt pathways, and in particular the Wnt/PCP branch, have been much less studied. Signal transduction from the Wnt/Frizzled/Dsh complex proceeds through unique protein components, including VANGL, PRICKLE, CELSR . This signaling activates the Rho GTPases Rac, Cdc42, and RhoA, which in turn modulate cytoskeleton structure and gene transcription. The Wnt/PCP pathway regulates planar cell polarity as well as the coordinated cell movement in embryos during gastrulation. The Wnt/Frizzled/Dsh complex also stimulates the Wnt calcium pathway by increasing intracellular calcium and activating two calcium dependent kinases, calmodulin-dependent protein kinase II (CAMKII) and protein kinase C (PKC).</text><annotation id="577"><infon key="identifier">207</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3785</infon><location length="3" offset="35351" /><text>Rac</text></annotation><annotation id="578"><infon key="identifier">998</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">123986</infon><location length="5" offset="35356" /><text>Cdc42</text></annotation><annotation id="579"><infon key="identifier">387</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68986</infon><location length="4" offset="35367" /><text>RhoA</text></annotation><annotation id="580"><infon key="identifier">8215</infon><infon key="type">Gene</infon><location length="3" offset="35584" /><text>Dsh</text></annotation><annotation id="581"><infon key="identifier">818</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">15596</infon><location length="38" offset="35718" /><text>calmodulin-dependent protein kinase II</text></annotation><annotation id="582"><infon key="identifier">818</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">15596</infon><location length="6" offset="35758" /><text>CAMKII</text></annotation><annotation id="583"><infon key="identifier">5578</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">55679</infon><location length="3" offset="35788" /><text>PKC</text></annotation><annotation id="584"><infon key="identifier">8215</infon><infon key="type">Gene</infon><location length="3" offset="35220" /><text>Dsh</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>35794</offset><text>To our knowledge, this is the first observation of the selective enhancement of the Wnt/PCP pathway and inhibition of the canonical Wnt pathway in lung SCC. Although the direct evidence of Wnt/PCP pathway in cancer development is sparse, its potential involvement in tumor progression, angiogenesis, invasion and metastasis has been the focus of recent research. Several groups have identified WNT5A as a key regulator of metastasis in melanoma, breast and gastric cancers. In addition both FZD7 and FZD10 have been shown to regulate migration and metastasis of gastric, colorectal and synovial carcinomas via the non-canonical Wnt signaling cascade. Furthermore, inhibition of VANGL1, an essential component of Wnt/PCP pathway that is overexpressed in SCC, was found to inhibit the size and metastatic potential of gastric tumors in mice. Due to its role in regulating cell adhesion and cell migration in response to microenvironmental cues, it is not surprising the Wnt/PCP pathway is emerging as a central player in tumor invasion and metastasis.</text><annotation id="603"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="35946" /><text>SCC</text></annotation><annotation id="604"><infon key="identifier">7474</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20720</infon><location length="5" offset="36188" /><text>WNT5A</text></annotation><annotation id="605"><infon key="identifier">8324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20751</infon><location length="4" offset="36285" /><text>FZD7</text></annotation><annotation id="606"><infon key="identifier">11211</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">21411</infon><location length="5" offset="36294" /><text>FZD10</text></annotation><annotation id="607"><infon key="identifier">229658</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">44540</infon><location length="6" offset="36472" /><text>VANGL1</text></annotation><annotation id="608"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="36547" /><text>SCC</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>36844</offset><text>Interestingly, the SCC samples in Group 2b do not share the Wnt/PCP pathway signature ( Figure 4 ), and every validation data set examined also contained a small number of SCC samples without activation of Wnt/PCP signaling. We are unable to find any secondary correlates that associate with this SCC subclass. The clinical relevance of this subset of SCC samples that lack the Wnt/PCP pathway signature is still an open question, but these findings suggest a potential avenue of study for patient stratification.</text><annotation id="623"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="36863" /><text>SCC</text></annotation><annotation id="624"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="37016" /><text>SCC</text></annotation><annotation id="625"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="37196" /><text>SCC</text></annotation><annotation id="626"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="37141" /><text>SCC</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>37358</offset><text>Until recently, SCC and AC were treated with a very similar clinical approach. In this study, we present a clear molecular pathway that is highly associated with these two subtypes of. Our analysis indicates that the Wnt/PCP expression is significantly different between a subgroup of SCC and AC. We believe that these results provide important insights on the mechanisms of SCC formation. Moreover, we suggest that targeting individual components of this pathway may also be of therapeutic interest.</text><annotation id="631"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="37643" /><text>SCC</text></annotation><annotation id="632"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="37374" /><text>SCC</text></annotation><annotation id="633"><infon key="identifier">6317</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">130559</infon><location length="3" offset="37733" /><text>SCC</text></annotation></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>37859</offset><text>Supporting Information</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>37882</offset><text>Competing Interests: The authors have declared that no competing interests exist.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>37964</offset><text>Funding: These authors have no support or funding to report.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>38025</offset><text>References</text></passage><passage><infon key="volume">6</infon><infon key="name_2">surname:Powell;given-names:CA</infon><infon key="name_1">surname:Toonkel;given-names:RL</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Borczuk;given-names:AC</infon><infon key="fpage">152</infon><infon key="pub-id_pmid">19349483</infon><infon key="year">2009</infon><infon key="source">Proc Am Thorac Soc</infon><infon key="type">ref</infon><infon key="lpage">158</infon><offset>38036</offset><text>Genomics of lung cancer.</text></passage><passage><infon key="volume">23</infon><infon key="name_2">surname:Vidal-Puig;given-names:A</infon><infon key="name_1">surname:Oresic;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Curtis;given-names:RK</infon><infon key="fpage">429</infon><infon key="pub-id_pmid">15950303</infon><infon key="year">2005</infon><infon key="source">Trends Biotechnol</infon><infon key="type">ref</infon><infon key="lpage">435</infon><offset>38061</offset><text>Pathways to the analysis of microarray data.</text></passage><passage><infon key="volume">19</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Werner;given-names:T</infon><infon key="fpage">50</infon><infon key="pub-id_pmid">18207385</infon><infon key="year">2008</infon><infon key="source">Curr Opin Biotechnol</infon><infon key="type">ref</infon><infon key="lpage">54</infon><offset>38106</offset><text>Bioinformatics applications for pathway analysis of microarray data.</text></passage><passage><infon key="name_3">surname:Lane;given-names:HC</infon><infon key="volume">4</infon><infon key="name_2">surname:Sherman;given-names:BT</infon><infon key="name_1">surname:Dennis G;suffix:Jr</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Hosack;given-names:DA</infon><infon key="fpage">R70</infon><infon key="pub-id_pmid">14519205</infon><infon key="year">2003</infon><infon key="source">Genome Biol</infon><infon key="type">ref</infon><infon key="name_4">surname:Lempicki;given-names:RA</infon><offset>38175</offset><text>Identifying biological themes within lists of genes with EASE.</text></passage><passage><infon key="name_3">surname:Mukherjee;given-names:S</infon><infon key="name_2">surname:Mootha;given-names:VK</infon><infon key="name_1">surname:Tamayo;given-names:P</infon><infon key="name_0">surname:Subramanian;given-names:A</infon><infon key="fpage">15545</infon><infon key="pub-id_pmid">16199517</infon><infon key="year">2005</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">102</infon><infon key="section_type">REF</infon><infon key="lpage">15550</infon><infon key="name_4">surname:Ebert;given-names:BL</infon><offset>38238</offset><text>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.</text></passage><passage><infon key="volume">57</infon><infon key="name_1">surname:Hochberg;given-names:Y</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Benjamini;given-names:Y</infon><infon key="fpage">289</infon><infon key="year">1995</infon><infon key="source">Journal of the Royal Statistical Society Series B-Methodological</infon><infon key="type">ref</infon><infon key="lpage">300</infon><offset>38345</offset><text>Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing.</text></passage><passage><infon key="name_3">surname:Lee;given-names:J</infon><infon key="name_2">surname:Kim;given-names:SH</infon><infon key="name_1">surname:Son;given-names:DS</infon><infon key="name_0">surname:Lee;given-names:ES</infon><infon key="fpage">7397</infon><infon key="pub-id_pmid">19010856</infon><infon key="year">2008</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="section_type">REF</infon><infon key="lpage">7404</infon><infon key="name_4">surname:Jo;given-names:J</infon><offset>38439</offset><text>Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.</text></passage><passage><infon key="volume">127</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Clevers;given-names:H</infon><infon key="fpage">469</infon><infon key="pub-id_pmid">17081971</infon><infon key="year">2006</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="lpage">480</infon><offset>38605</offset><text>Wnt/beta-catenin signaling in development and disease.</text><annotation id="641"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="38609" /><text>beta-catenin</text></annotation></passage><passage><infon key="volume">55</infon><infon key="name_1">surname:Dey;given-names:A</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Paul;given-names:S</infon><infon key="fpage">165</infon><infon key="pub-id_pmid">18348648</infon><infon key="year">2008</infon><infon key="source">Neoplasma</infon><infon key="type">ref</infon><infon key="lpage">176</infon><offset>38660</offset><text>Wnt signaling and cancer development: therapeutic implication.</text></passage><passage><infon key="name_3">surname:Yu;given-names:S</infon><infon key="name_2">surname:Mermel;given-names:CH</infon><infon key="name_1">surname:Watanabe;given-names:H</infon><infon key="name_0">surname:Bass;given-names:AJ</infon><infon key="fpage">1238</infon><infon key="pub-id_pmid">19801978</infon><infon key="year">2009</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="section_type">REF</infon><infon key="lpage">1242</infon><infon key="name_4">surname:Perner;given-names:S</infon><offset>38723</offset><text>SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.</text><annotation id="646"><infon key="identifier">6657</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68298</infon><location length="4" offset="38723" /><text>SOX2</text></annotation></passage><passage><infon key="volume">9</infon><infon key="name_1">surname:du Manoir;given-names:S</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Hussenet;given-names:T</infon><infon key="fpage">1480</infon><infon key="pub-id_pmid">20372069</infon><infon key="year">2010</infon><infon key="source">Cell Cycle</infon><infon key="type">ref</infon><infon key="lpage">1486</infon><offset>38819</offset><text>SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis.</text><annotation id="651"><infon key="identifier">6657</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68298</infon><location length="4" offset="38819" /><text>SOX2</text></annotation></passage><passage><infon key="name_3">surname:Tang;given-names:X</infon><infon key="volume">5</infon><infon key="name_2">surname:Behrens;given-names:C</infon><infon key="name_1">surname:Kadara;given-names:H</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Yuan;given-names:P</infon><infon key="fpage">e9112</infon><infon key="pub-id_pmid">20161759</infon><infon key="year">2010</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="name_4">surname:Woods;given-names:D</infon><offset>38908</offset><text>Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.</text><annotation id="657"><infon key="identifier">6657</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68298</infon><location length="30" offset="38908" /><text>Sex determining region Y-Box 2</text></annotation><annotation id="658"><infon key="identifier">6657</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">68298</infon><location length="4" offset="38940" /><text>SOX2</text></annotation></passage><passage><infon key="name_3">surname:Hrychyk;given-names:A</infon><infon key="name_2">surname:Hartmann;given-names:W</infon><infon key="name_1">surname:Waha;given-names:A</infon><infon key="name_0">surname:Koch;given-names:A</infon><infon key="fpage">4295</infon><infon key="pub-id_pmid">15958610</infon><infon key="year">2005</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="section_type">REF</infon><infon key="lpage">4304</infon><infon key="name_4">surname:Schuller;given-names:U</infon><offset>39057</offset><text>Elevated expression of Wnt antagonists is a common event in hepatoblastomas.</text></passage><passage><infon key="volume">14</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Katoh;given-names:M</infon><infon key="fpage">1583</infon><infon key="pub-id_pmid">16273260</infon><infon key="year">2005</infon><infon key="source">Oncol Rep</infon><infon key="type">ref</infon><infon key="lpage">1588</infon><offset>39134</offset><text>WNT/PCP signaling pathway and human cancer (review).</text></passage><passage><infon key="name_3">surname:Liu;given-names:G</infon><infon key="name_2">surname:Bafico;given-names:A</infon><infon key="name_1">surname:Yaniv;given-names:A</infon><infon key="name_0">surname:Golan;given-names:T</infon><infon key="fpage">14879</infon><infon key="pub-id_pmid">14747478</infon><infon key="year">2004</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">279</infon><infon key="section_type">REF</infon><infon key="lpage">14888</infon><infon key="name_4">surname:Gazit;given-names:A</infon><offset>39187</offset><text>The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt. beta-catenin signaling cascade.</text><annotation id="670"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="10" offset="39197" /><text>Frizzled 6</text></annotation><annotation id="671"><infon key="identifier">8323</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2617</infon><location length="4" offset="39209" /><text>HFz6</text></annotation><annotation id="672"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="39266" /><text>beta-catenin</text></annotation></passage><passage><infon key="name_3">surname:Masu;given-names:M</infon><infon key="volume">13</infon><infon key="name_2">surname:Keino-Masu;given-names:K</infon><infon key="name_1">surname:Uchida;given-names:H</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Shiomi;given-names:K</infon><infon key="fpage">73</infon><infon key="pub-id_pmid">12526749</infon><infon key="year">2003</infon><infon key="source">Curr Biol</infon><infon key="type">ref</infon><infon key="lpage">77</infon><offset>39298</offset><text>Ccd1, a novel protein with a DIX domain, is a positive regulator in the Wnt signaling during zebrafish neural patterning.</text><annotation id="676"><infon key="identifier">360137</infon><infon key="type">Gene</infon><location length="4" offset="39298" /><text>Ccd1</text></annotation></passage><passage><infon key="name_3">surname:Zou;given-names:H</infon><infon key="name_2">surname:Deng;given-names:Y</infon><infon key="name_1">surname:Luo;given-names:W</infon><infon key="name_0">surname:Wong;given-names:CK</infon><infon key="fpage">39366</infon><infon key="pub-id_pmid">15262978</infon><infon key="year">2004</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">279</infon><infon key="section_type">REF</infon><infon key="lpage">39373</infon><infon key="name_4">surname:Ye;given-names:Z</infon><offset>39420</offset><text>The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase activation by Axin and dishevelled through distinct mechanisms.</text><annotation id="679"><infon key="identifier">8312</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2614</infon><location length="4" offset="39507" /><text>Axin</text></annotation></passage><passage><infon key="name_3">surname:Yukita;given-names:A</infon><infon key="name_2">surname:Suzuki;given-names:T</infon><infon key="name_1">surname:Yamamoto;given-names:H</infon><infon key="name_0">surname:Kadoya;given-names:T</infon><infon key="fpage">3803</infon><infon key="pub-id_pmid">11997515</infon><infon key="year">2002</infon><infon key="source">Mol Cell Biol</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="section_type">REF</infon><infon key="lpage">3819</infon><infon key="name_4">surname:Fukui;given-names:A</infon><offset>39557</offset><text>Desumoylation activity of Axam, a novel Axin-binding protein, is involved in downregulation of beta-catenin.</text><annotation id="683"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="39652" /><text>beta-catenin</text></annotation><annotation id="684"><infon key="identifier">8312</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2614</infon><location length="4" offset="39597" /><text>Axin</text></annotation></passage><passage><infon key="volume">25</infon><infon key="name_2">surname:Dedhar;given-names:S</infon><infon key="name_1">surname:Syam;given-names:S</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Oloumi;given-names:A</infon><infon key="fpage">7747</infon><infon key="pub-id_pmid">16799642</infon><infon key="year">2006</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="lpage">7757</infon><offset>39666</offset><text>Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells.</text><annotation id="689"><infon key="identifier">89780</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22528</infon><location length="5" offset="39680" /><text>Wnt3a</text></annotation><annotation id="690"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="39703" /><text>beta-catenin</text></annotation></passage><passage><infon key="volume">133</infon><infon key="name_1">surname:Cepko;given-names:CL</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Cho;given-names:SH</infon><infon key="fpage">3167</infon><infon key="pub-id_pmid">16854977</infon><infon key="year">2006</infon><infon key="source">Development</infon><infon key="type">ref</infon><infon key="lpage">3177</infon><offset>39790</offset><text>Wnt2b/beta-catenin-mediated canonical Wnt signaling determines the peripheral fates of the chick eye.</text><annotation id="695"><infon key="identifier">374243</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22526</infon><location length="5" offset="39790" /><text>Wnt2b</text></annotation><annotation id="696"><infon key="identifier">395964</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="39796" /><text>beta-catenin</text></annotation></passage><passage><infon key="name_3">surname:Runyan;given-names:RB</infon><infon key="name_2">surname:Krieg;given-names:PA</infon><infon key="name_1">surname:Garriock;given-names:RJ</infon><infon key="name_0">surname:Person;given-names:AD</infon><infon key="fpage">35</infon><infon key="pub-id_pmid">15649459</infon><infon key="year">2005</infon><infon key="source">Dev Biol</infon><infon key="type">ref</infon><infon key="volume">278</infon><infon key="section_type">REF</infon><infon key="lpage">48</infon><infon key="name_4">surname:Klewer;given-names:SE</infon><offset>39892</offset><text>Frzb modulates Wnt-9a-mediated beta-catenin signaling during avian atrioventricular cardiac cushion development.</text><annotation id="702"><infon key="identifier">2487</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1126</infon><location length="4" offset="39892" /><text>Frzb</text></annotation><annotation id="703"><infon key="identifier">7483</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20722</infon><location length="6" offset="39907" /><text>Wnt-9a</text></annotation><annotation id="704"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="39923" /><text>beta-catenin</text></annotation></passage><passage><infon key="name_3">surname:Gladon;given-names:J</infon><infon key="name_2">surname:Twedt;given-names:J</infon><infon key="name_1">surname:Brimeyer;given-names:R</infon><infon key="name_0">surname:Westfall;given-names:TA</infon><infon key="fpage">889</infon><infon key="pub-id_pmid">12952939</infon><infon key="year">2003</infon><infon key="source">J Cell Biol</infon><infon key="type">ref</infon><infon key="volume">162</infon><infon key="section_type">REF</infon><infon key="lpage">898</infon><infon key="name_4">surname:Olberding;given-names:A</infon><offset>40005</offset><text>Wnt-5/pipetail functions in vertebrate axis formation as a negative regulator of Wnt/beta-catenin activity.</text><annotation id="707"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="40090" /><text>beta-catenin</text></annotation></passage><passage><infon key="name_3">surname:Ruschhaupt;given-names:M</infon><infon key="name_2">surname:Meister;given-names:M</infon><infon key="name_1">surname:Muley;given-names:T</infon><infon key="name_0">surname:Kuner;given-names:R</infon><infon key="fpage">32</infon><infon key="pub-id_pmid">18486272</infon><infon key="year">2009</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">63</infon><infon key="section_type">REF</infon><infon key="lpage">38</infon><infon key="name_4">surname:Buness;given-names:A</infon><offset>40113</offset><text>Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes.</text></passage><passage><infon key="name_3">surname:Sengupta;given-names:S</infon><infon key="volume">1</infon><infon key="name_2">surname:Den Boon;given-names:JA</infon><infon key="name_1">surname:Quintana;given-names:FA</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Newton;given-names:MA</infon><infon key="fpage">85</infon><infon key="year">2007</infon><infon key="source">Annals of Applied Statistics</infon><infon key="type">ref</infon><infon key="lpage">106</infon><infon key="name_4">surname:Ahlquist;given-names:P</infon><offset>40229</offset><text>Random-Set Methods Identify Distinct Aspects of the Enrichment Signal in Gene-Set Analysis.</text></passage><passage><infon key="volume">25</infon><infon key="name_2">surname:Medvedovic;given-names:M</infon><infon key="name_1">surname:Leikauf;given-names:GD</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Sartor;given-names:MA</infon><infon key="fpage">211</infon><infon key="pub-id_pmid">19038984</infon><infon key="year">2009</infon><infon key="source">Bioinformatics</infon><infon key="type">ref</infon><infon key="lpage">217</infon><offset>40321</offset><text>LRpath: a logistic regression approach for identifying enriched biological groups in gene expression data.</text></passage><passage><infon key="name_3">surname:Li;given-names:C</infon><infon key="name_2">surname:Staunton;given-names:J</infon><infon key="name_1">surname:Richards;given-names:WG</infon><infon key="name_0">surname:Bhattacharjee;given-names:A</infon><infon key="fpage">13790</infon><infon key="pub-id_pmid">11707567</infon><infon key="year">2001</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">98</infon><infon key="section_type">REF</infon><infon key="lpage">13795</infon><infon key="name_4">surname:Monti;given-names:S</infon><offset>40428</offset><text>Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.</text></passage><passage><infon key="name_3">surname:Edgerton;given-names:M</infon><infon key="name_2">surname:Yanagisawa;given-names:K</infon><infon key="name_1">surname:Shyr;given-names:Y</infon><infon key="name_0">surname:Yamagata;given-names:N</infon><infon key="fpage">4695</infon><infon key="pub-id_pmid">14581339</infon><infon key="year">2003</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="section_type">REF</infon><infon key="lpage">4704</infon><infon key="name_4">surname:Dang;given-names:TP</infon><offset>40541</offset><text>A training-testing approach to the molecular classification of resected non-small cell lung cancer.</text></passage><passage><infon key="name_3">surname:Isagawa;given-names:T</infon><infon key="name_2">surname:Hoshida;given-names:Y</infon><infon key="name_1">surname:Fujiwara;given-names:T</infon><infon key="name_0">surname:Inamura;given-names:K</infon><infon key="fpage">7105</infon><infon key="pub-id_pmid">16007138</infon><infon key="year">2005</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="section_type">REF</infon><infon key="lpage">7113</infon><infon key="name_4">surname:Jones;given-names:MH</infon><offset>40641</offset><text>Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization.</text></passage><passage><infon key="name_3">surname:Chen;given-names:G</infon><infon key="name_2">surname:Yu;given-names:J</infon><infon key="name_1">surname:Zhang;given-names:Y</infon><infon key="name_0">surname:Raponi;given-names:M</infon><infon key="fpage">7466</infon><infon key="pub-id_pmid">16885343</infon><infon key="year">2006</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="section_type">REF</infon><infon key="lpage">7472</infon><infon key="name_4">surname:Lee;given-names:G</infon><offset>40819</offset><text>Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.</text></passage><passage><infon key="name_3">surname:Liu;given-names:Y</infon><infon key="name_2">surname:Hoadley;given-names:KA</infon><infon key="name_1">surname:Yin;given-names:X</infon><infon key="name_0">surname:Wilkerson;given-names:MD</infon><infon key="fpage">4864</infon><infon key="pub-id_pmid">20643781</infon><infon key="year">2010</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="section_type">REF</infon><infon key="lpage">4875</infon><infon key="name_4">surname:Hayward;given-names:MC</infon><offset>40921</offset><text>Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.</text></passage><passage><infon key="volume">129</infon><infon key="name_2">surname:Moon;given-names:RT</infon><infon key="name_1">surname:Conrad;given-names:WH</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Chien;given-names:AJ</infon><infon key="fpage">1614</infon><infon key="pub-id_pmid">19177135</infon><infon key="year">2009</infon><infon key="source">J Invest Dermatol</infon><infon key="type">ref</infon><infon key="lpage">1627</infon><offset>41052</offset><text>A Wnt survival guide: from flies to human disease.</text></passage><passage><infon key="name_3">surname:Aghamohammadi;given-names:N</infon><infon key="volume">59</infon><infon key="name_2">surname:Liebler;given-names:J</infon><infon key="name_1">surname:Li;given-names:C</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Borok;given-names:Z</infon><infon key="fpage">84R</infon><infon key="year">2006</infon><infon key="source">Pediatr Res</infon><infon key="type">ref</infon><infon key="lpage">93R</infon><infon key="name_4">surname:Londhe;given-names:VA</infon><offset>41103</offset><text>Developmental pathways and specification of intrapulmonary stem cells.</text></passage><passage><infon key="volume">5</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Rawlins;given-names:EL</infon><infon key="fpage">675</infon><infon key="pub-id_pmid">18684716</infon><infon key="year">2008</infon><infon key="source">Proc Am Thorac Soc</infon><infon key="type">ref</infon><infon key="lpage">681</infon><offset>41174</offset><text>Lung epithelial progenitor cells: lessons from development.</text></passage><passage><infon key="name_3">surname:Maeda;given-names:O</infon><infon key="name_2">surname:Ito;given-names:G</infon><infon key="name_1">surname:Kondo;given-names:M</infon><infon key="name_0">surname:Fukui;given-names:T</infon><infon key="fpage">6323</infon><infon key="pub-id_pmid">16007200</infon><infon key="year">2005</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="section_type">REF</infon><infon key="lpage">6327</infon><infon key="name_4">surname:Sato;given-names:N</infon><offset>41234</offset><text>Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer.</text><annotation id="729"><infon key="identifier">6422</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2266</infon><location length="35" offset="41263" /><text>secreted frizzled related protein 1</text></annotation><annotation id="730"><infon key="identifier">6422</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2266</infon><location length="6" offset="41300" /><text>SFRP 1</text></annotation></passage><passage><infon key="name_3">surname:Xu;given-names:Z</infon><infon key="name_2">surname:You;given-names:L</infon><infon key="name_1">surname:He;given-names:B</infon><infon key="name_0">surname:Mazieres;given-names:J</infon><infon key="fpage">4717</infon><infon key="pub-id_pmid">15256437</infon><infon key="year">2004</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">64</infon><infon key="section_type">REF</infon><infon key="lpage">4720</infon><infon key="name_4">surname:Lee;given-names:AY</infon><offset>41368</offset><text>Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.</text><annotation id="735"><infon key="identifier">11197</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">31430</infon><location length="23" offset="41368" /><text>Wnt inhibitory factor-1</text></annotation></passage><passage><infon key="name_3">surname:Gaspert;given-names:A</infon><infon key="name_2">surname:Okamoto;given-names:Y</infon><infon key="name_1">surname:Kros;given-names:JM</infon><infon key="name_0">surname:Ohgaki;given-names:H</infon><infon key="fpage">197</infon><infon key="pub-id_pmid">15072829</infon><infon key="year">2004</infon><infon key="source">Cancer Lett</infon><infon key="type">ref</infon><infon key="volume">207</infon><infon key="section_type">REF</infon><infon key="lpage">203</infon><infon key="name_4">surname:Huang;given-names:H</infon><offset>41455</offset><text>APC mutations are infrequent but present in human lung cancer.</text></passage><passage><infon key="name_3">surname:Fearon;given-names:ER</infon><infon key="name_2">surname:Kolligs;given-names:FT</infon><infon key="name_1">surname:Kohno;given-names:T</infon><infon key="name_0">surname:Sunaga;given-names:N</infon><infon key="fpage">316</infon><infon key="pub-id_pmid">11170292</infon><infon key="year">2001</infon><infon key="source">Genes Chromosomes Cancer</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="section_type">REF</infon><infon key="lpage">321</infon><infon key="name_4">surname:Saito;given-names:R</infon><offset>41518</offset><text>Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma.</text><annotation id="748"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="6" offset="41574" /><text>CTNNB1</text></annotation><annotation id="749"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="41582" /><text>beta-catenin</text></annotation></passage><passage><infon key="name_3">surname:Mengistab;given-names:A</infon><infon key="volume">1</infon><infon key="name_2">surname:Sidhu;given-names:SS</infon><infon key="name_1">surname:Dasari;given-names:V</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Lemjabbar-Alaoui;given-names:H</infon><infon key="fpage">e93</infon><infon key="pub-id_pmid">17183725</infon><infon key="year">2006</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="name_4">surname:Finkbeiner;given-names:W</infon><offset>41648</offset><text>Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer.</text></passage><passage><infon key="name_3">surname:Kim;given-names:JY</infon><infon key="name_2">surname:Zhang;given-names:XH</infon><infon key="name_1">surname:Chiang;given-names:AC</infon><infon key="name_0">surname:Nguyen;given-names:DX</infon><infon key="fpage">51</infon><infon key="pub-id_pmid">19576624</infon><infon key="year">2009</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">138</infon><infon key="section_type">REF</infon><infon key="lpage">62</infon><infon key="name_4">surname:Kris;given-names:MG</infon><offset>41728</offset><text>WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.</text><annotation id="758"><infon key="identifier">3172</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">395</infon><location length="3" offset="41732" /><text>TCF</text></annotation><annotation id="759"><infon key="identifier">51176</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7813</infon><location length="4" offset="41754" /><text>LEF1</text></annotation><annotation id="760"><infon key="identifier">3219</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7367</infon><location length="5" offset="41763" /><text>HOXB9</text></annotation></passage><passage><infon key="volume">6</infon><infon key="name_1">surname:Okamoto;given-names:H</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Wada;given-names:H</infon><infon key="fpage">3</infon><infon key="pub-id_pmid">19250033</infon><infon key="year">2009</infon><infon key="source">Zebrafish</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>41810</offset><text>Roles of noncanonical Wnt/PCP pathway genes in neuronal migration and neurulation in zebrafish.</text></passage><passage><infon key="volume">38</infon><infon key="name_1">surname:Moon;given-names:RT</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Kohn;given-names:AD</infon><infon key="fpage">439</infon><infon key="pub-id_pmid">16099039</infon><infon key="year">2005</infon><infon key="source">Cell Calcium</infon><infon key="type">ref</infon><infon key="lpage">446</infon><offset>41906</offset><text>Wnt and calcium signaling: beta-catenin-independent pathways.</text><annotation id="766"><infon key="identifier">1499</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1434</infon><location length="12" offset="41933" /><text>beta-catenin</text></annotation></passage><passage><infon key="volume">8</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Wang;given-names:Y</infon><infon key="fpage">2103</infon><infon key="pub-id_pmid">19671746</infon><infon key="year">2009</infon><infon key="source">Mol Cancer Ther</infon><infon key="type">ref</infon><infon key="lpage">2109</infon><offset>41968</offset><text>Wnt/Planar cell polarity signaling: a new paradigm for cancer therapy.</text></passage><passage><infon key="volume">6</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Jessen;given-names:JR</infon><infon key="fpage">21</infon><infon key="pub-id_pmid">19292672</infon><infon key="year">2009</infon><infon key="source">Zebrafish</infon><infon key="type">ref</infon><infon key="lpage">28</infon><offset>42039</offset><text>Noncanonical Wnt signaling in tumor progression and metastasis.</text></passage><passage><infon key="name_3">surname:Seo;given-names:YW</infon><infon key="name_2">surname:Chay;given-names:KO</infon><infon key="name_1">surname:Park;given-names:SR</infon><infon key="name_0">surname:Lee;given-names:JH</infon><infon key="fpage">4235</infon><infon key="pub-id_pmid">15205336</infon><infon key="year">2004</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">64</infon><infon key="section_type">REF</infon><infon key="lpage">4243</infon><infon key="name_4">surname:Kook;given-names:H</infon><offset>42103</offset><text>KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer.</text><annotation id="777"><infon key="identifier">81839</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">44540</infon><location length="42" offset="42103" /><text>KAI1 COOH-terminal interacting tetraspanin</text></annotation><annotation id="778"><infon key="identifier">81839</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">44540</infon><location length="7" offset="42147" /><text>KITENIN</text></annotation><annotation id="779"><infon key="identifier">3732</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20512</infon><location length="4" offset="42208" /><text>KAI1</text></annotation></passage><passage><infon key="name_3">surname:Ardizzoni;given-names:A</infon><infon key="volume">9</infon><infon key="name_2">surname:Gelsomino;given-names:F</infon><infon key="name_1">surname:Bartolotti;given-names:M</infon><infon key="section_type">REF</infon><infon key="name_0">surname:Tiseo;given-names:M</infon><infon key="fpage">425</infon><infon key="pub-id_pmid">19374597</infon><infon key="year">2009</infon><infon key="source">Expert Rev Anticancer Ther</infon><infon key="type">ref</infon><infon key="lpage">435</infon><offset>42280</offset><text>First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype.</text></passage></document></collection>